CytomX Therapeutics Inc (CTMX)
4.489
-0.64
(-12.49%)
USD |
NASDAQ |
May 02, 16:00
4.74
+0.25
(+5.59%)
Pre-Market: 08:24
CytomX Therapeutics Revenue (Quarterly): 26.61M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 26.61M |
| September 30, 2023 | 26.38M |
| June 30, 2023 | 24.72M |
| March 31, 2023 | 23.50M |
| December 31, 2022 | 20.12M |
| September 30, 2022 | 11.15M |
| June 30, 2022 | 12.85M |
| March 31, 2022 | 9.04M |
| December 31, 2021 | -12.53M |
| September 30, 2021 | 17.59M |
| June 30, 2021 | 16.29M |
| March 31, 2021 | 15.97M |
| December 31, 2020 | -15.56M |
| September 30, 2020 | 17.79M |
| June 30, 2020 | 16.61M |
| March 31, 2020 | 49.59M |
| December 31, 2019 | -22.31M |
| September 30, 2019 | 10.71M |
| June 30, 2019 | 9.013M |
| Date | Value |
|---|---|
| March 31, 2019 | 29.48M |
| December 31, 2018 | 11.47M |
| September 30, 2018 | 12.51M |
| June 30, 2018 | 21.34M |
| March 31, 2018 | 14.18M |
| December 31, 2017 | 27.07M |
| September 30, 2017 | 24.14M |
| June 30, 2017 | 8.752M |
| March 31, 2017 | 11.65M |
| December 31, 2016 | 6.272M |
| September 30, 2016 | 3.454M |
| June 30, 2016 | 3.094M |
| March 31, 2016 | 2.223M |
| December 31, 2015 | 1.988M |
| September 30, 2015 | 1.939M |
| June 30, 2015 | 2.043M |
| March 31, 2015 | 1.742M |
| December 31, 2014 | 1.861M |
| September 30, 2014 | 1.915M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-22.31M
Minimum
Dec 2019
49.59M
Maximum
Mar 2020
13.55M
Average
16.29M
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Ocular Therapeutix Inc | 14.80M |
| Bristol-Myers Squibb Co | 11.86B |
| ACADIA Pharmaceuticals Inc | 231.04M |
| Cytokinetics Inc | 1.672M |
| Calidi Biotherapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.837M |
| Total Expenses (Quarterly) | 27.21M |
| EPS Diluted (Quarterly) | 0.01 |
| Enterprise Value | 129.50M |
| Profit Margin (Quarterly) | 3.15% |
| Earnings Yield | -0.45% |
| Normalized Earnings Yield | -0.4455 |